A Randomised, Double-blinded, Multiple-dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC9204-1706 in Subjects Being Overweight or With Obesity
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs NN-9423 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 17 Oct 2019 Status changed from active, no longer recruiting to completed.
- 09 Oct 2019 Planned End Date changed from 5 Sep 2019 to 12 Oct 2019.
- 09 Oct 2019 Status changed from recruiting to active, no longer recruiting.